Philadelphia chromosome positive chronic myeloid leukemia has a progressive course starting in a benign phase and terminating in a blastic phase. In this study, we show that human homolog double minute 2 (HDM2) inhibition, with MI-219Fa novel compound, and consequently p53 stabilization induce chronic myeloid leukemia (CML) blast crisis cells to undergo apoptosis regardless of the presence of the T315I mutation in the BCR-ABL kinase domain. The response to MI-219 is associated with the downregulation of c-Myc and the induction of p21
Introduction
The chromosomal translocation involving chromosomes 9 and 22 distinguishes the hematological malignancy chronic myeloid leukemia (CML) 1, 2 and produces a constitutively active BCR-ABL tyrosine kinase directly involved in development of the disease. BCR-ABL promotes the activation of various pathways regulating growth and survival, while not dramatically affecting differentiation. These pathways include the MAP-kinase, 3 Akt/ PI3K/mTOR 4 and Jak/Stat 5, 6 each contributing to growth advantages while protecting cells from the apoptotic process. BCR-ABL also regulates many other RNA-binding proteins involved in translational, transcriptional and mRNA export mechanisms, 7 which in turn affect various factors such as C/EBPa, E2F3 and Bcl-XL, important in differentiation, growth and survival, respectively.
CML is a progressive disease evolving from a chronic through an accelerated to the terminal blast crisis phase. These transitions are believed to be associated with further acquisition of mutation(s) and/or epigenetic changes. Resistance to therapy with tyrosine kinase inhibitors is more commonly seen in progressive disease and is frequently associated with point mutations in BCR-ABL kinase domain. 8, 9 However, the precise amount of genetic events required or involved in the transition of disease is ill defined.
The tumor suppressor TP53 (also known as p53) is often mutated 10 in solid tumors, while in the blast-crisis phase of CML approximately 20% of patients display mutated p53.
11 BCR-ABL is also reported to regulate translation of the E3 ubiquitin ligase HDM2 and consequently affects the level of p53 protein. 12 The p53 protein network regulates important mechanisms of DNA damage repair, cell cycle regulation/checkpoints, senescence and apoptosis. 13 Its role in apoptosis is highlighted by its ability to positively regulate the expression of various pro-apoptotic genes such as Bax, PUMA, Noxa, p53AIP1 and p53DINP1. 14, 15 More recent observations identified re-localization of p53 protein to the mitochondrial compartment as an alternative mode of direct nontranscriptional apoptotic action of p53. Mitochondrial p53 is reported to activate pro-apoptotic proteins by displacing them from anti-apoptotic proteins [16] [17] [18] and promoting release of cytochrome c to trigger apoptosis.
Fine tuning of p53 activity is controlled by modification of the protein itself through acetylation, phosphorylation, sumoylation, and methylation. 10 Its association with the HDM2 E3-ligase protein promotes its ubiquitin-dependent degradation. Strategies to enhance p53 tumor-suppressive function through its stabilization have been developed with small molecules such as Nutlin, MI-63 and MI-219, [19] [20] [21] which block the interaction between p53 and HDM2, effectively stabilizing p53 protein levels This results in growth arrest and apoptosis in various tumor cells. 22 In this study, we assess the ability of the HDM2-inhibitor MI-219 20 to promote apoptosis in CML blast crisis cells. Our results show that this strategy engages an apoptotic response in CML blast cells independent of the presence of mutant BCR-ABL. We also show that both transcriptional dependent and independent mechanisms of p53-mediated apoptosis are engaged by stabilization of p53 in CML blast crisis cells. These observations suggest that p53 stabilization may be an attractive therapeutic option for blast crisis CML.
Materials and methods
Cell lines, cell culture, retroviral shRNA-mediated knockdown and patient information CML cell lines WDT2, WDT3, K562, K562R, BV173 and BV173R were cultured in RPMI (Roswell Park Memorial Institute-1640) with 2 mM L-glutamine, 50 U/ml penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA), with 10% heat-inactivated fetal bovine serum (Hyclone, Thermoscientific, Rockford, IL, USA) (RPMI-complete). Peripheral blood from blast crisis patients was obtained under informed consent of patients following the guidelines of the Institutional Review Board of the University of Michigan. The samples were processed by a Ficoll (GE Health Care, Piscataway, NJ, USA) gradient at 800 g for 20 min and the interphase-collected cells were washed twice with phosphate-buffered saline (PBS). Cells were then stored in 10% dimethylsulfoxide in heat-inactivated fetal bovine serum at À80 1C overnight and moved to liquid nitrogen storage tanks. For the culture of primary CML cells, tubes were thawed and washed once with PBS and resuspended in 10 ml PBS with 1000 U/ml DNAse (Sigma-Aldrich, St Louis, MO, USA), and incubated 20-30 min at 37 1C. Cells were diluted to 5 Â 10 6 to 1 Â 10 7 /ml in RPMI-complete and rested overnight in a humidified 37 1C incubator with 5% CO 2 . The following day dead cells were removed by a Ficoll gradient (as described above). DNA was extracted from patient cells for genomic sequence analysis of p53 exons 3-4, exon 5-6, exon 7 and exon 8-9 as previously described. 23 Knockdown of p53 was achieved with the following sense targeting sequence: p53; 5 0 -GACTCCAGTGGTAATCTAC-3 0 cloned into pRetrosuperpuro (Oligoengine, Seattle, WA, USA). 24 Noxa knockdown was achieved using the pRetrosuper-EGFP-Noxa7 and control short hair pin RNA (shRNA) retroviral constructs provided by Dr E Eldering (Academic Medical Center, Amsterdam, The Netherlands). 25 Virus was produced and the cell lines were spin-infected as described previously, 26 or spin-infected with 2 mg/ml lipofectamine (Invitrogen) for 2 h at 32 degrees at 3200 r.p.m. Cells were selected with 1 mg/ml puromycin or EGFP þ cells isolated by cell sorting on the FacsAria (BD Biosciences, Rockville, MD, USA).
Isolation and analysis of CD34 þ primary peripheral blood or bone marrow CML blast crisis cells CD34 þ cells from patients in blast crisis or from normalmobilized stem cell donors were isolated using Miltenyi CD34 þ magnetic beads as described by the manufacturer (Miltenyi, Auburn, CA, USA), using PBS-2 mM EDTA-0.5% human serum albumin (Sigma-Aldrich). The purity (85-99%) was determined by CD34-R-phycoerythrin staining. CD34 and CD95 expression analysis was performed by washing cells with PBS, resuspension in 100 ml PBS-2 mM EDTA-0.5% human serum albumin with 5 ml CD34-R-phycoerythrin (Miltenyi), or 20 ml of CD95-Alexa488 (eBioscience, San Diego, CA, USA) and incubation for 20 min on ice. Cells were washed with PBS and resuspended in PBS-2 mM EDTA-0.5% human serum albumin with 1 mg/ml 4 0 ,6-diamidino-2-phenylindole dihydrochloride (Sigma-Aldrich) to exclude dead cells. Flow cytometry was done on the FACSCANTO-II (BD Biosciences) and final analysis was performed with Flowjo (Tree Star, Inc., Ashland, OR, USA).
Treatment of cell lines or primary blasts crisis CML progenitors for western or apoptosis assays
Nutlin-3a was purchased from Cayman chemicals (Ann Arbor, MI, USA) and imatinib was purified from discarded Gleevec pills by William Bornman (MD Anderson, Houston, TX, USA). MI-219 was synthesized in the department of Pharmacology and Toxicology at the University of Michigan as described. 20 All compounds were dissolved in dimethylsulfoxide (SigmaAldrich). Cell lines were treated with MI-219 and/or imatinib at concentrations described in Figures 1 and 2 , with cell densities starting at 4 or 5 Â 10 5 /ml. Primary blasts crisis CML progenitor cells were plated at 1 Â 10 5 /ml of serum-free expansion media (Stem Cell Technologies; Vancouver, BC, Canada) with 40 mg/ml low-density lipoprotein (Sigma-Aldrich), 50 ng/ml SCF and Flt3 and 10 ng/ml IL3, IL6, IL-7 and G-CSF (Peprotech, Rocky Hill, NJ, USA). Apoptosis analysis was performed by staining with Annexin V-FITC (Southern Biotech, Birmingham, AL, USA) as described by the manufacturer, and analyzed on the FACSCANTO-II (BD Biosciences). Total protein cell lysates were prepared by lysing cells in Urea-Laemli buffer (60 mM Tris pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 0.5% b-mercaptoethanol, 1 M urea and 0.05% bromphenol blue) at 1 Â 10 8 /ml. RNA was prepared from primary samples with the mirVana isolation kit (Ambion, Austin, TX, USA) following the manufacturer's instructions. For real-time PCR analysis, cDNA was prepared with the RT-superscript (Invitrogen) and real-time PCR was performed with sybergreen for the indicated p53 target genes (http://www.realtimepcr.com) in triplicate on the Bio-Rad iCycler (Bio-Rad, Hercules, CA, USA), and DDCt values were calculated to determine fold changes.
Western blots analysis and cell fractionation
Fractionation of cytoplasmic and mitochondrial fractions was performed as previously described 27 using 3 Â 10 7 cells. Western blotting was performed by resolving proteins by SDS-PAGE on a 7-18% gradient gel that was transferred to nitrocellulose, and blocked with 3% milk-PBS, 0.5% Tween20. Antibodies were diluted in 1% milk-PBST or 0.5% BSA-PBST and incubated overnight at 4 1C. The antibodies were as follows:
rabbit-anti-phospho-Stat5, rabbit-anti-PARP, rabbit-anti-cleaved caspase-3, rabbit-anti-BclXL (Cell Signaling Technologies, Danvers, MA, USA), rabbit-anti-HDM4, rabbit-antip73 (Bethyl Laboratories, Montgomery, TX, USA), rabbit-anti-p53, mouse-anti-Grp75 (Abcam, Cambridge, MA, USA), rabbit-antiRunx1, mouse-anti-Noxa (Novus Biologicals, Littleton, CO, USA), and rabbit-anti-actin (Sigma-Aldrich). Secondary antibodies were donkey-anti-rabbit, sheep-anti-mouse, or donkey-anti-goat horseradish-peroxidase conjugates (Santa-Cruz); and chemiluminescence was performed with enhanced chemiluminescence (NEN, Boston, MA, USA) and exposed to film (Denville Scientific, Metuchen, NJ, USA).
Results

Inhibition of HDM2 induces apoptosis in CML blast crisis cell lines
HDM2 inhibitors are reported to stabilize p53 and induce cell growth arrest and apoptosis in solid tumor and leukemic cell lines. 22, 28 We examined the effect of MI-219 on BCR-ABLpositive CML and a B-ALL cell line. Figure 1a , shows that treatment of the p53 wild-type WDT2 CML myeloid blast crisis cell line with 5 mM of MI-219 or Nutlin-3a induced 60.2 and 53.4% apoptosis, respectively. Western blot analysis demonstrated increased p53 protein at 2.5 mM MI-219, induction of the p53 target genes p21 WAF1 and activated apoptotic caspases were verified by the appearance of cleaved PARP 29 ( Figure 1b ). These effects were not associated with BCR-ABL kinase inhibition as phosphor-CrkL 30 was not affected. HDM2 inhibitor activity was dependent on p53 as MI-219 did not induce p21 WAF1 or apoptosis in p53 null K562 CML cells (Figure 1b ). Although the p53 family member, p73 has been implicated in HDM2 inhibitor stabilization, 31 we observed only a slight increase in 
HDM2 inhibition bypasses BCR-ABL mutation-associated resistance
Next we analyzed the ability of HDM2 inhibition to induce apoptosis in CML cells with T315I mutant BCR-ABL expression. The BV173R imatinib-resistant T315I mutant cell line 32 was equally sensitive to HDM2 inhibition as the parental BV173 (Figure 1c) . Further, p53 was stabilized by MI-219, whereas imatinib did not significantly alter p53 protein levels (Figure 1d ). Stabilized p53 was associated with an increase in its downstream targets PUMA and p21
WAF1
, while Stat5-Y694 phosphorylation was not suppressed. Thus MI-219 treatment engages the p53 pathway and apoptosis of CML and B-ALL cells that express kinase-inhibitor-resistant T315I BCR-ABL mutation.
HDM2 modulates protein expression in CML cell lines
Treatment of WDT2 cells with 2.5 mM MI-219 for 6 or 16 h in the presence or absence of 0.5 mM imatinib induced several changes in protein expression (Figure 2a) . Specifically, c-Myc that is positively regulated by BCR-ABL through the Akt-signaling pathway 4 is markedly downregulated by the combination of MI-219 and imatinib. Less effective reduction in c-Myc levels was noted in cells treated with either compound alone. In addition, the expression of the anti-apoptotic BCR-ABL target protein MCL1 33 was decreased, whereas the expression of the pro-apoptotic protein PUMA was increased. We also observed decreased expression of full length Bid suggesting cleavage and formation of truncated pro-apoptotic Bid. 34 HDM4, the p53 negative transcriptional regulator and family member of HDM2, was downregulated by MI-219 whereas imatinib had no influence on its expression. Its downregulation suggests that the reported ubiquitin ligase activity of HDM2 . Cells were treated with indicated concentrations of MI-219 and analyzed on day 2 for apoptosis as described above. WDT2 and K562 cells were prepared for western blot analysis of p53 levels; 16 h post MI-219 treatment. PARP cleavage indicative of apoptosis was also detected in WDT2, as well as induction of the p53 target, p21 WAF1 . The BCR-ABL target protein phospho-Crkl is not affected by MI-219. Ponceau staining was used as protein-loading control. (c) BV173 and the BCR-ABL T315I mutant BV173R were analyzed for apoptosis as described above following incubation with the indicated dose of MI-219 or Nutlin-3a. The expression of the indicated proteins was assessed by western blotting BV173R cell lysates after 16 h of treatment with 2.5 mM MI-219 in the presence or absence of 0.5 mM imatinib.
p53 stabilization induces apoptosis LF Peterson et al towards HDM4 is engaged. 35 Lastly, phosphorylated Stat5 is decreased efficiently by imatinib. 36 Thus, the single agent or combined MI-219 treatment of CML cells with imatinib decreases expression of various proteins involved in BCR-ABL transformation and survival, while promoting the induction of pro-apoptotic genes downstream of the p53. Lastly, MI-219 also induced the FAS receptor (CD95), in a dose-dependent manner (Figure 2b) . 37 This induction led to only a small additive apoptotic response after the addition of 20 ng/ml Fas ligand during MI-219 treatment (data not shown). Further, the caspase-3 inhibitor (DEVD-CHO) and the pan-caspase inhibitor (ZVAD-FMK) counteracted the apoptotic response of CML cells to MI-219 (Figure 2d) . Specifically, the caspase-3 inhibitor was less effective at low dose; however, we cannot discount the possibility that this variation is due to a differential of DVED-CHO as compared with ZVAD-FMK in getting into the cells. Lastly, caspase inhibition with ZVAD-FMK did not interfere with p53 stabilization, upregulation of its targets genes HDM2 and Bax or downregulation of c-Myc, whereas it did reverse the cleavage of Parp, Bid, MCL-1 and caspase-3. Thus these observations suggest that a predominant intrinsic and a weak extrinsic pathway, involving the CD95 signaling, of apoptosis are engaged by stabilized p53 protein in CML cells.
Mitochondrial accumulation of p53 by MI-219 treatment
The release of cytochrome c from the mitochondria is an important step in the induction of programmed cell death. 38 Various reports implicate mitochondrial p53 as an additional mechanism in the control of cytochrome c release from the mitochondia. [16] [17] [18] Mitochondrial p53 disengages pro-apoptotic factors such as Bax, Bad and Bak from anti-apoptotic factors such as BCL-2, BclxL or MCL1 leading to cytochrome c release. 39 Mitochondrial and cytoplasmic fractions of CML cells treated with MI-219 show an increase of mitochondrial and cytoplasmic p53 levels (Figure 3a) . Contrarily, the nuclearspecific transcription factor Runx1, not modulated by MI-219 treatment, did not accumulate in the mitochondrial or cytoplasmic fraction. The cytoplasmic protein HSP90 was absent from the mitochondrial preparation, whereas the mitochondrial protein GRP75 was enriched in the mitochondrial fraction, next to the apoptosis regulators BCL-2 and Noxa. Thus, the proposed p53 non-transcriptional intrinsic apoptotic effect was engaged by MI-219 stabilization of p53 in CML cells.
Knockdown of p53 and target gene Noxa differentially affects the apoptotic response to MI-219
We observed that the p53 null cell line K562 does not undergo apoptosis with MI-219. To specifically address the importance of p53, we used shRNA targeting p53 with the pRetrosuper retroviral system. We infected the myeloid and lymphoid Ph þ cell lines WDT2 and BV173, respectively, making two independent pools for each line. Decreased p53 protein levels are observed, which attenuated apoptosis in the presence of MI-219 (Figures 3b and c) , the induction of p21 WAF1 and Noxa is attenuated as well (Figure 3d ). However, p53 protein stabilization, increase in p21 WAF1 and Noxa are maintained following exposure to MI 219 in the control shRNA line.
Noxa, a known p53 target is associated with apoptosis through its ability to counteract the survival factor MCL-1. Furthermore, BCR-ABL is known to positively regulate MCL-1 expression. 33 We therefore analyzed the impact of Noxa knockdown with shRNA on the apoptotic response of CML cells. The level of knockdown we achieved was approximately 50% (Figures 3e and f) in two independent pools of two Ph þ cell lines. MI-219-promoted apoptosis was only minimally, but statistically significant, counteracted in these cells compared with the control shRNA lines (Figures 3e and f) . Thus knockdown of p53 and its target Noxa show a differential ability to counteract MI-219 apoptotic response of these cells to p53 stabilization.
Primary blast crisis CML cells undergo p53-induced apoptosis
As described above we observed significant apoptotic responses in both BCR-ABL positive blast crisis CML and ALL cells, irrespective of the presence of the T315I imatinib-resistant mutation. To assess if similar activities are also engaged in primary blast crisis samples, we performed apoptotic assays with myeloid or lymphoid blast crisis CD34 þ -enriched cells from nine patient samples. Peripheral blood samples were analyzed for BCR-ABL and p53 mutational status ( Table 1) . As shown in Figure 4 , the cells undergo apoptosis in the presence of MI-219 over a 3-day period with varying degrees of sensitivity to MI-219. Apoptotic responses were observed in five patient samples (responders; 48-21% survival) (Figure 4a) . Further, normal CD34 þ cells showed reduced apoptosis to 2.5 mmol of MI-219 compared with CML cells (Po0.001) (Figure 4a ) . Two patient samples showed no response (non-responders; 73-90% survival) (Figure 4b ), and two additional patient samples had only moderate response (65-68% survival) (Figure 4c ). p53-sequencing analysis showed a wild-type pattern of all samples with several samples having codon 72 P72R, p53 polymorphism in one or both alleles (Table 1 ). Resistance to MI-219 is therefore not mediated by p53 mutations.
To investigate if pretreatment with MI-219 followed by a second dose of the same concentration of MI-219 would affect the survival of the moderate responders, we treated these cells with MI-219 for 3 days followed by a second dose of the same concentration, then performed apoptosis analysis on day 6 . Under these conditions we demonstrated that the samples undergo significant apoptosis (Figure 4d) .
We investigated CD95 expression in a set of primary blast crisis cells following treatment for two days with MI-219, and WAF1 and Noxa induction levels in a BV173 shp53 clone with 5 mM MI-219 for 5 h. Actin was used for protein-loading control. (e,f) Noxa knockdown partially affects MI-219 apoptosis. As described in b and c, two independent pools of Noxa (7.1 and 7.2) knockdown WDT2 and BV173 were prepared and analyzed for apoptosis following MI-219 treatment. Western blot insert depicts the level of Noxa knockdown in each pool. (Figure 4e , bottom panel) also showed an increase of CD95 expression. Thus, irrespective of their individual sensitivity to MI-219, primary blast crisis cells increase CD95/FAS receptor levels because of p53's ability to positively regulate its promoter. 37 Analysis of gene expression of pro-apoptotic targets of p53 showed that contrary to sensitive patients the resistant patient showed a significant decrease in FAS ligand, DR5, p53AIP1 and APAF1 and the tumor suppressor/apoptosis regulator TP53BP2 (Figure 4f ). We observed a small non-synergistic, additive effect by MI-219 and FasLG that may be due to the fact that blast crisis cells express high CD95 levels following progression, 41 the latter may have paradoxical adversarial effect through engagement of the PI3-K/AKT survival signal, 42 and having a role in chemotherapy resistance. 43 Finally, two samples from MI-219 resistant and sensitive patients were subjected to 5 mM of MI-219 for 16 h and assessed for induction of p53, HDM2, p21 WAF1 and decrease of HDM4. All of these proteins were equally modulated in the MI-219 sensitive and resistant cases (Figure 4g ). However, analysis of the pro-apoptotic targets Bax and Noxa shows that the resistant patient 7, as compared with the responding patient 9, had similar induction of Bax but not Noxa. These observations suggest that p53 stabilization by MI-219 is not always sufficient to induce apoptosis in blast crisis CML cells, and that other 'downstream' cellular changes in addition to unknown epigenetic/genetic events may be associated with resistance.
p53 stabilization induces apoptosis
LF Peterson et al observed that patients with sensitivity to MI-219 (Figure 4e, top and middle panel) displayed increased CD95 expression. Cells from one resistant patient
Discussion
Imatinib has dramatically altered the survival outcome of patients with CML. 44 However, either primary or acquired resistance was present in a substantial fraction of patients. BCR-ABL kinase domain point mutations were found to be associated with therapy resistance in about 50% of these patients. 45, 46 Second generation tyrosine kinase inhibitors Nilotinib and Dasatinib provided effective therapy for many of these patients. These treatments were however ineffective against the T315I mutation, which directly interferes with TKI's binding to the ATP pocket. 47 Furthermore, CML primitive progenitors LinÀ/CD38À/ CD34 þ cells, are refractory to the effect of TKIs, [48] [49] [50] and may be the cause of persistent disease after therapy with TKIs.
MI-219 enhances p53 (TP53) stability and function through its ability to block the association between p53 and its E3 ubiquitin ligase negative regulator HDM2. 20 TP53 mutations affecting its function are not common in chronic phase disease and are detected in only about 20% of patients in blast crisis. 11 Furthermore, acute myeloid leukemia 51 and blast crisis CML display increased expression of HDM2. 12 In CML, upregulation of HDM2 is promoted by BCR-ABL itself through the regulation of the La-antigen protein that enhances HDM2 translation. 12 In addition BCR-ABL is suggested to affect the function of various RNA-binding proteins affecting the expression of C/EBPa, 52 c-Myc 53 and E2F3 54 during progression of indolent chronic CML to blast crisis. TP53 protein's role in hematopoiesis was demonstrated through its induction of hematopoietic failure by ionizing radiation, 55 and its role in the maintenance of hematopoietic stem cell quiescence. 56, 57 However, short-term treatment of normal CD34 þ progenitor cells with the HDM2-inhibitor Nutlin-3a inhibited the clonogenic ability of these cells to a lesser extent than treatment of these cells with fludarabine, a well-known chemotherapeutic nucleoside used in the treatment of B-CLL. 58 We investigated the ability of HDM2 inhibition and p53 stabilization to induce apoptosis in CML blast crisis cells. P72R is a polymorphism in exon 4, codon 72 of p53 leading to a proline-to-arginine substitution present in both normal and tumor DNA. p53 stabilization induces apoptosis LF Peterson et al mitochondrial accumulation. [16] [17] [18] The pro-apoptotic effect of MI-219 and p53 stabilization was also noted in five of nine primary human blast crises or Ph þ ALL cells, irrespective of the presence of activating mutations in BCR-ABL. This effect was increased by prolonged exposure to MI-219. In two additional samples we failed to note significant apoptosis. Furthermore, we provide the first clear evidence that HDM2 inhibition has a reduced effect on normal CD34 þ cells compared with CML blast crisis cells.
It is evident from clinical outcome data that treatment with BCR-ABL inhibitors is insufficient to control CML blast crisis, either because therapy is ineffective or because of rapidly evolving resistance. 59, 60 Strategies directed against other cellular targets are essential in managing this advanced condition. In addition to our observations on the role of p53 stabilization, other investigators have studied the impact of inhibition of other cell-signaling pathways. A role for Wnt signaling in progression of chronic phase to blast crisis CML 61, 62 has been proposed. Further, b-catenin, the regulator of Wnt signaling, is required for efficient BCR-ABL leukemogenesis in mice. 63 The loss of the Smoothen receptor, important for Hedgehog signaling, alters the course of BCR-ABL-induced leukemia, and treatment of blast crisis patient cells with Hedgehog-signaling inhibitor cyclopamine blocked leukemic blast colony formation. 64 Lastly, cyclopamine treatment of BCR-ABL-transformed murine bone marrow decreased their ability to transmit leukemia.
The p53 protein negatively regulates important transcription factors in both the Hedgehog and the Wnt-signaling pathway. Specifically, p53 negatively affects GLI1 transcriptional activity. 65 The Wnt transcriptional regulators b-catenin and TCF4 are negatively regulated by p53 through degradation 66 and direct negative transcriptional regulation, 67 respectively. In addition, the increased HDM2 protein level caused by Hedgehog 68 and BCR-ABL 12 signaling can be counteracted by MI-219. 35 Therefore, p53 control of multiple CML pathways may be appropriate for therapeutic intervention. In this report, we demonstrate that MI-219 stabilizes p53 and induces an apoptotic response in primary blast crisis cells irrespective of the presence of BCR-ABL mutation(s). This is accomplished through involvement of both transcriptional and non-transcriptional activities of p53 promoting apoptosis. We also observed resistance to MI-219 induced apoptosis in two of nine patients. A similar observation of resistance to MI-219 was recently described in B30% of AML patients with wild-type p53. 69 These observations suggest the requirement of future investigations to identify mechanism(s) of resistance to HDM2 inhibition, employing shRNA library studies to elucidate pathways that disrupt MI-219 action. Further a thorough gene expression profiling coupled with apoptosis analysis is required in patient sets of responders and non-responders, to establish a sensible choice of patients that will positively respond to MI-219 treatment. Our observations provide a rational for clinical use of an HDM2 inhibitor in the treatment of blast crisis CML.
